Product Detail
Indicine N-Oxide-D7
Indicine Metabolite
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Metabolite
API Family
Indicine
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
Indicine N-Oxide-D7 Product Information
Indicine N-Oxide-D7 is listed under Metabolite. It is associated with Indicine and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-96391.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
Indicine N-Oxide-D7
CAS No.
-
CAT No.
CS-T-96391
Molecular Formula
C15H18D7NO6
Molecular Weight
322.41
Category
API Family
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Indicine N-Oxide-D7
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"Indicine N-oxide-D7 is a labelled analogue of Indicine N-oxide (I521105). Indicine N-oxide is a pyrrolizidine alkaloid that is isolated from Heliotropium indicum, one of the most widely used herbs in India. Indicine N-oxide exhibits antitumour and antimitotic activity in humans, and has subsequently undergone Phase I & II trials in adults and children with leukemia and solid tumours."
Synonyms
"(2R,3S)-2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid [(1R,7aS)-2,3,5,7a-Tetrahydro-1-hydroxy-4-oxido-1H-pyrrolizin-7-yl]methyl Ester-D7; [1R-[1a,7(2R*,3S*),7aß]]-2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-Tetrahydro-1-hydroxy-1H-pyrrolizin-7-y"
Application Notes
"Indicine N-oxide-D7 is a labelled analogue of Indicine N-oxide (I521105). Indicine N-oxide is a pyrrolizidine alkaloid that is isolated from Heliotropium indicum, one of the most widely used herbs in India. Indicine N-oxide exhibits antitumour and antimitotic activity in humans, and has subsequently undergone Phase I & II trials in adults and children with leukemia and solid tumours."
References
"Kovach, J., et al.: Cancer Res., 39, 4540 (1979); Powis, G., et al.: Cancer Res., 39, 3564 (1979); Whitehead, V., et al.: Cancer Chemo. Pharma., 26, 377 (1990)"